Logo

Pfizer Initiates Study to Evaluate its Pneumococcal Vaccine with Booster dose of its COVID-19 Vaccine

Share this

Pfizer Initiates Study to Evaluate its Pneumococcal Vaccine with Booster dose of its COVID-19 Vaccine

Shots:

  • The first enrolled patient has received their immunizations as part of a new study in adults ≥65yrs. evaluating the coadministration of 20vPnC with a booster dose of the Pfizer-BioNTech’s COVID-19 vaccine
  • The trial will include ~600 adults who will be recruited from the P-III COVID-19 vaccine trial and will have received their second dose of the vaccine at least 6mos. before entering the coadministration study
  • The primary objective in the trial is to describe safety when both vaccines are co-administered- with follow up 6mos. after vaccination. The secondary objective is to describe immune responses produced by each of the vaccines

  Ref: Pfizer | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions